Download PDF
Z Gastroenterol 2004; 42(9): 1017-1020
DOI: 10.1055/s-2004-813494
Leitlinien

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Remissionserhaltung

Maintenance TherapyW. Kruis1 , S. Schreiber2
  • 1Abt. Innere Medizin, Evangelisches Krankenhaus Köln-Kalk
  • 2I. Medizinische Klinik, Christian-Albrechts-Universität zu Kiel
Further Information

Publication History

Publication Date:
04 October 2004 (online)

Also available at
    Permissions and Reprints

Definition

Empfehlung
Die Remission der CU wird klinisch definiert. Kriterien der Remission sind Abwesenheit von Diarrhö (nicht > 3 Stühle/d), kein sichtbares Blut im Stuhl sowie keine durch die CU bedingten intestinalen oder extraintestinalen Beschwerden (C).

Erläuterung
Von den verschiedenen Kriterien Klinik, Morphologie und Labor ist das klinische Kriterium als einziges in allen wissenschaftlichen Untersuchungen, die für die Therapieentscheidung herangezogen werden, enthalten. Keine Einigkeit besteht in der Wahl eines bestimmten Aktivitätsindex zur Definition der Remission oder Definitionen basierend auf Laborwerten oder einer Koloskopie. Definition der Remission aufgrund von Rektoskopie/Sigmoidoskopie oder von Histologie oder von Sonographie allein sollte nicht erfolgen. Die Remission darf nicht aufgrund eines Kontrasteinlaufs definiert werden (siehe auch „Klinische Diagnostik”). Es gibt Hinweise dafür, dass das zusätzliche Vorhandensein einer endoskopischen und histologischen Remission auch mit einer stabileren (d. h. länger dauernden) klinischen Remission einhergeht [1] [2] [3].

Literatur

  • 1 Courtney M G, Nunes D P, Bergin C F. et al . Colonoscopic but not histological appearances determine liklyhood of relapse of ulcerative colitis.  Am J Gastroenterol. 1991;  86 243 (III)
    PubMedGoogle Scholar
  • 2 Goodman M W, Eberle D E, Kuchler L A. et al . Microscopic activity predicts relapse in patients with distal ulcerative colitis on 4-Aminosalizylate enemas.  Gastroenterology. 1988;  96 (Suppl) A151 (III)
    PubMedGoogle Scholar
  • 3 Riley S A, Mani V, Goodman M J. et al . Microscopic activity in ulcerative colitis: what does it mean?.  Gut. 1991;  32 174-178 (IIa)
    CrossrefPubMedGoogle Scholar
  • 4 Ardizzone S, Petrillo M, Imbesi V. et al . Is maintenance therapy always necessary for patients with ulcerative colitis in remission?.  Aliment Pharmacol Ther. 1999;  13 373-379 (Ib)
    PubMedGoogle Scholar
  • 5 Kornbluth A A, Salomon P, Sacks H S. et al . Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis.  J Clin Gastroenterol. 1993;  16 215-218 (Ia)
    PubMedGoogle Scholar
  • 6 Sutherland L RD, Beck P. Alternatives to Sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis.  Inflamm Bowel Dis. 1997;  65-78 (Ia)
    PubMedGoogle Scholar
  • 7 Sutherland L R, May G R, Shaffer E A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.  Ann Intern Med. 1993;  118 540-549 (Ia)
    PubMedGoogle Scholar
  • 8 Marshall J K, Irvine E J. Rectal Aminosalizylate therapy for distal ulcerative colitis: a meta-analysis.  Aliment Pharmacol Ther. 1995;  9 293-300 (Ia)
    CrossrefPubMedGoogle Scholar
  • 9 d’Albasio G, Pacini F, Camarri E. et al . Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.  Am J Gastroenterol. 1997;  92 1143-1147 (Ib)
    PubMedGoogle Scholar
  • 10 Riley S A. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?.  Gut. 1998;  42 761-763 (IV)
    PubMedGoogle Scholar
  • 11 Azad K han AK, Howes D T, Piris J. et al . Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.  Gut. 1980;  21 232-240 (Ib)
    PubMedGoogle Scholar
  • 12 Fockens P, Mulder C J, Tytgat G N. et al . Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.  Eur J Gastroenterol Hepatol. 1995;  7 1025-1030 (Ib)
    PubMedGoogle Scholar
  • 13 Kiilerich S, Ladefoged K, Rannem T. et al . Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.  Gut. 1992;  33 252-255 (Ib)
    CrossrefPubMedGoogle Scholar
  • 14 Biddle W L, Greenberger N J, Swan J T. et al . 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis.  Gastroenterology. 1988;  94 1075-1079 (Ib)
    PubMedGoogle Scholar
  • 15 Mantzaris G J, Hatzis A, Petraki K. et al . Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.  Dis Colon Rectum. 1994;  37 58-62 (Ib)
    PubMedGoogle Scholar
  • 16 d’Albasio G, Trallori G, Ghetti A. et al . Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis.  Dis Colon Rectum. 1990;  33 394-397 (Ib)
    PubMedGoogle Scholar
  • 17 d’Albasio G, Paoluzi P, Campieri M. et al . Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group.  Am J Gastroenterol. 1998;  93 799-803 (Ib)
    PubMedGoogle Scholar
  • 18 Marteau P, Crand J, Foucault M. et al . Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.  Gut. 1998;  42 195-199 (Ib)
    CrossrefPubMedGoogle Scholar
  • 19 Carbonnel F, Boruchowicz A, Duclos B. et al . Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses.  Dig Dis Sci. 1996;  41 2471-2476 (III)
    PubMedGoogle Scholar
  • 20 Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome.  Dig Liver Dis. 2003;  35 546-551 (III)
    CrossrefPubMedGoogle Scholar
  • 21 Cohen R D, Stein R, Hanauer S B. Intravenous cyclosporin in ulcerative colitis: a five-year experience.  Am J Gastroenterol. 1999;  94 1587-1592 (III)
    CrossrefPubMedGoogle Scholar
  • 22 Cohen R D, Woseth D M, Thisted R A. et al . A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.  Am J Gastroenterol. 2000;  95 1263-1276 (Ia)
    CrossrefPubMedGoogle Scholar
  • 23 Kruis W, Schreiber S, Theuer D. et al . Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.  Gut. 2001;  49 783-789 (Ib)
    CrossrefPubMedGoogle Scholar
  • 24 Sandborn W J. Azathioprine: state of the art in inflammatory bowel disease.  Scand J Gastroenterol Suppl. 1998;  225 92-99 (IV)
    PubMedGoogle Scholar
  • 25 Lindgren S, Lofberg R, Bergholm L. et al . Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis.  Scand J Gastroenterol. 2002;  37 705-710 (Ib)
    CrossrefPubMedGoogle Scholar
  • 26 Meyers S, Lerer P K, Feuer E J. et al . Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial.  J Clin Gastroenterol. 1987;  9 50-54 (Ib)
    PubMedGoogle Scholar
  • 27 Kruis W, Schutz E, Fric P. et al . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.  Aliment Pharmacol Ther. 1997;  11 853-858 (Ib)
    CrossrefPubMedGoogle Scholar
  • 28 Rembacken B J, Snelling A M, Hawkey P M. et al . Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.  Lancet. 1999;  354 635-639 (Ib)
    CrossrefPubMedGoogle Scholar
  • 29 Kruis W, Fric P, Pokrotnieks J. et al . Maintaining remission of ulcerative colitis with the probiotic E. coli Nissle 1917 is as effective as with standard mesalazine.  Gut. 2004 (in press) (Ib); 
    PubMedGoogle Scholar
  • 30 Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana J L. et al . Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU).  Am J Gastroenterol. 1999;  94 427-433 (Ib)
    PubMedGoogle Scholar
  • 31 Pinczowski D, Ekbom A, Baron J. et al . Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.  Gastroenterology. 1994;  107 117-120 (III)
    CrossrefPubMedGoogle Scholar
  • 32 Moody G A, Jayanthi V, Probert C S. et al . Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.  Eur J Gastroenterol Hepatol. 1996;  8 1179-1183 (IIb)
    CrossrefPubMedGoogle Scholar
  • 33 Eaden J, Abrams K, Ekbom A. et al . Colorectal cancer prevention in ulcerative colitis: a case-control study.  Aliment Pharmacol Ther. 2000;  14 145-153 (III)
    PubMedGoogle Scholar

Prof. Dr. W. Kruis

Evangelisches Krankenhaus Köln-Kalk, Abt. Innere Medizin

Buchforststraße 2

51103 Köln

Phone: ++ 49/02 21/82 89-52 89

Fax: ++ 49/02 21/82 89-52 91

Email: kruis@evkk.de

      >